The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

NCT ID: NCT01052311

Last Updated: 2016-10-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2013-01-31

Brief Summary

Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) offers improved tolerability, supporting a simplified 1-2 g dosing paradigm and improved adherence. Statins and niacin improve endothelial function in cardiac patients, however, there is no data yet regarding the additive effects of raising HDL-C by ERN/LRPT and statins on endothelial function in cardiac patients. Thus the aim of the present study is to evaluate the impact of 3 months' administration of ERN/LRPT compared to placebo added to statins on endothelial function, assessed by brachial artery vasoreactivity in stable cardiac patients.

Detailed Description

Endothelial dysfunction reflects a vascular phenotype prone to atherogenesis and may therefore serve as a marker of an inherent atherosclerotic risk. In line with this hypothesis, dysfunction of either the coronary or peripheral vascular endothelium was shown to constitute an independent predictor of cardiovascular events, providing valuable prognostic information additional to that derived from conventional risk factor assessment. Interventions, such as risk factor modification and treatment with various drugs, including statins and niacin, may improve endothelial function leading potentially to improve prognosis.

Research over the past years has identified numerous beneficial effects of high-density lipoprotein (HDL) beyond this property. These include, but not limited to, improvement of endothelial function, anti-inflammatory, anti-thrombotic, antioxidative effects and the stimulation of endothelial regeneration. Consequently, therapeutic elevation of HDL is among the primary goals of treatment of patients with coronary artery disease (CAD). Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) offers improved tolerability, supporting a simplified 1-2 g dosing paradigm and improved adherence. Statins and niacin improve endothelial function in CAD patients, however, there is no data yet regarding the additive effects of raising HDL-C by ERN/LRPT and statins on endothelial function in CAD patients. Thus the aim of the present study is to evaluate the impact of 3 months' administration of ERN/LRPT compared to placebo added to statins on endothelial function, assessed by brachial artery vasoreactivity, and platelet function in stable CAD patients .

Conditions

Coronary Artery Disease; Dyslipidemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Placebo pills once daily

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo tablets once daily

Active treatment

Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.

Group Type: ACTIVE_COMPARATOR

Tredaptive (1 g extended release niacin+ 20 mg laropiprant)

Intervention Type: DRUG

Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.

Tredaptive

Intervention Type: DRUG

Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.

Interventions

Tredaptive (1 g extended release niacin+ 20 mg laropiprant)

Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.

Intervention Type: DRUG

Placebo

Placebo tablets once daily

Intervention Type: DRUG

Tredaptive

Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.

Intervention Type: DRUG

Other Intervention Names

Active treatment; Tedaptive

Eligibility Criteria

Inclusion Criteria

1. Male or female ≥ 18 years; signed informed consent

2. Outpatient CAD patients on statin therapy.

3. HDL-C < 40 mg/dL in males and < 50 mg/dL in females.

4. Left ventricular (LV) systolic dysfunction ≥ 40% measured within the past 6 months.

5. No changes in cardiac medications during 2 weeks prior to enrollment.

Exclusion Criteria

1. Presence of transplanted tissue or organ or LVAD

2. AICD or CRT or CRTD patients.

3. Acute MI, CABG, PCI within past 3 months.

4. Congestive heart failure (CHF) ≥ NYHA 2.

5. Ejection fraction < 40% measured within the past 6 months.

6. Malignancy.

7. Active myocarditis, or cardiomyopathy.

8. HIV infection or immunodeficiency state.

9. Chronic viral infection.

10. Acute systemic infection requiring antibiotics.

11. Chronic diarrhea or malabsorption.

12. Statin therapy initiation ≤ 3 months.

13. Diabetes mellitus type 1.

14. Diabetes mellitus type 2 with HbA1C > 7%

15. Low-density lipoprotein cholesterol (LDL-C) > 100 mg/dL.

16. Not on statin therapy.

17. Liver function tests (LFT) ≥ x 3 upper limit of normal (ULN) or creatinine kinase (CPK) ≥ x 10 ULN.

18. Hypo/hyper thyroidism.

19. Liver dysfunction.

20. Renal failure with serum creatinine ≥ 2 mg/dL.

21. Alcohol or drug abuse.

22. Refuse to sign informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sheba Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Shechter, MD, MA

Role: PRINCIPAL_INVESTIGATOR

Leviev Heart Center, Sheba Medical Center

Shlomi Matetzky, MD

Role: STUDY_DIRECTOR

Leviev Heart Center, Sheba Medical Center

Locations

Leviev Heart Center, Sheba Medical Center

Tel Litwinsky, , Israel

Countries

Israel

Other Identifiers

SHEBA-09-7418-MS-CTIL

Identifier Type: -

Identifier Source: org_study_id